Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00810576 · OUTCOME

Number of Patients With Response

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma · Source last updated 2012-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Every two 21-day cycles

What was measured

Computed tomography scans and/or Positron emission tomography (PET) scans obtained every two cycles to evaluate response using International Workshop Criteria of Complete Response, Partial Response, Progressive Disease, or Stable Disease.

Analysis population: No analysis done due to early termination resulting from low accrual.

Groups in this outcome

Vorinostat + Bortezomib

Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\^2 intravenously on Days 1, 4, 8, 11.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vorinostat + Bortezomib1

Reported measurements

Complete Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Vorinostat + Bortezomib0Not reportedNot reportedNot reportedNot reported
Partial Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Vorinostat + Bortezomib0Not reportedNot reportedNot reportedNot reported
Progressive Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Vorinostat + Bortezomib1Not reportedNot reportedNot reportedNot reported
Stable Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Vorinostat + Bortezomib0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Partial Response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Progressive Disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Stable Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Computed tomography scans and/or Positron emission tomography (PET) scans obtained every two cycles to evaluate response using International Workshop Criteria of Complete Response, Partial Response, Progressive Disease, or Stable Disease.
groups
  1. description
    Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m\^2 intravenously on Days 1, 4, 8, 11.
    id
    OG000
    title
    Vorinostat + Bortezomib
param Type
NUMBER
population Description
No analysis done due to early termination resulting from low accrual.
reporting Status
POSTED
time Frame
Every two 21-day cycles
title
Number of Patients With Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice